Viva Biotech Holdings disclosed that its issued share capital remained unchanged at 2.13 billion ordinary shares as of 27 May 2026, despite an active share-buyback programme during the month.

Key takeaways

1. Latest daily repurchase • On 27 May 2026 the company bought back 0.60 million shares on the Hong Kong Stock Exchange at HK$1.33–1.34 per share, spending HK$0.80 million.

2. Cumulative May buybacks pending cancellation • Between 8–27 May 2026, Viva Biotech repurchased 15.22 million shares, equivalent to 0.72% of the company’s issued share base. • The aggregate cash outlay for these repurchases totals approximately HK$22.68 million, implying an average purchase price of about HK$1.49 per share. • All repurchased shares are earmarked for cancellation but had not yet been cancelled as of 27 May 2026.

3. Repurchase mandate utilisation • The current buybacks represent 7.15% of the 212.84 million shares authorised for repurchase under the mandate granted on 12 June 2025. • Following the latest transaction, Viva Biotech is subject to a 30-day moratorium—until 26 June 2026—before it can issue new shares or sell any treasury shares.

Outlook The company’s programme reflects ongoing capital management efforts without altering the total number of issued shares to date. All repurchases have been executed in compliance with Hong Kong Stock Exchange regulations, as confirmed by Executive Director Mao Chen Cheney.